Cruzipain

Description:

Description
  • Accession: P25779
  • Swissprot: CYSP_TRYCR
  • Organism: Trypanosoma cruzi
  • Target class: Enzyme

Drug Relations:

amiodarone
An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. Bioactivity details MOA
candesartan cilexetil
a nonpeptide angiotensin II receptor antagonist Bioactivity details MOA
clofazimine
A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619) Bioactivity details MOA
etravirine
HIV-1 reverse transriptase inhibitor; an anti-HIV agent Bioactivity details MOA
fenofibrate
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood. Bioactivity details MOA
gefitinib
Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor, thereby inhibiting further downstream signalling and blocking EGFR-dependent proliferation. Bioactivity details MOA
itraconazole
A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis. Bioactivity details MOA
manidipine
Bioactivity details MOA
menatetrenone
Bioactivity details MOA
methylthioninium chloride
A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN. Bioactivity details MOA
pranlukast
SRS-A antagonist; leukotriene D4 receptor antagonist Bioactivity details MOA
raloxifene
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. Bioactivity details MOA
triclabendazole
Benzimidazole antiplatyhelmintic agent that is used for the treatment of FASCIOLIASIS and PARAGONIMIASIS. Bioactivity details MOA